The company now expects to end 2027 with approximately $700 million in cash and no term debt. This represents an increase of $400 million to prior 2027 net cash guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- FDA Extends BioCryst’s ORLADEYO Review Deadline
- BioCryst Stockholders Approve Stock Incentive Plan Amendment
- BioCryst announces new data on efficacy, safety of ORLADEYO
- BioCryst announces INVIMA in Colombia approved ORLADEYO
- BioCryst achieves reimbursement for ORLADEYO across major European countries